We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

BATA:PSXBata Pakistan Limited Analysis

Data as of 2026-03-17 - not real-time

IDR 468.00

Latest Price

8/10Risk

Risk Level: High

Executive Summary

The stock trades below its short‑term, intermediate‑term and long‑term moving averages, underscoring bearish price action. RSI sits near the neutral zone, while the MACD histogram remains negative, confirming downward momentum. Volume has been on a downtrend, and recent volatility is exceptionally high, indicating a choppy market. Fundamentally, the price‑to‑earnings multiple is more than double the industry average, suggesting the stock is overvalued. A payout ratio near the upper limit raises concerns about dividend sustainability given the high leverage. The balance sheet shows a debt‑to‑equity ratio well above typical thresholds, amplifying financial risk.
Despite a solid dividend yield, the company's revenue growth is flat and operating margins are thin, limiting upside potential. Cash reserves are sizable but are dwarfed by total debt, leaving little cushion. The low beta indicates limited correlation with broader market moves, yet the high volatility and decreasing liquidity amplify trading risk. The discounted cash flow model places fair value far below the current price, reinforcing the overvaluation view. Given these dynamics, the stock appears better suited for cautious positioning rather than aggressive buying. Investors should monitor debt reduction progress and dividend policy before taking a cautious, longer‑term stance.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 6/10

Key Factors

  • price below all moving averages
  • negative MACD histogram
  • high volatility

Medium Term

1–3 years
Neutral
Model confidence: 5/10

Key Factors

  • substantial dividend yield
  • flat revenue growth
  • elevated debt levels

Long Term

> 3 years
Cautious
Model confidence: 7/10

Key Factors

  • significant overvaluation relative to DCF
  • persistent high leverage
  • limited growth prospects

Key Metrics & Analysis

Financial Health

Revenue Growth-0.20%
Profit Margin11.68%
P/E Ratio36.5
ROE8.37%
ROA2.94%
Debt/Equity85.51
P/B Ratio3.3
Op. Cash FlowIDR188.2B
Industry P/E16.5

Technical Analysis

TrendBearish
RSI47.7
SupportIDR 400.00
ResistanceIDR 700.00
MA 20IDR 479.20
MA 50IDR 496.58
MA 200IDR 543.45
MACDBearish
VolumeDecreasing
Fear & Greed Index78.73

Valuation

Fair ValueIDR 65.37
GradeOvervalued
TypeValue
Dividend Yield2.68%

Risk Assessment

Beta0.12
Volatility84.14%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskMedium
Liquidity RiskHigh

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.